...Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria... ...two therapeutics companies, two medtechs and a diagnostics company. One, the acquisition of immuno-oncology company Rigontec GmbH... ...milestones. The upfront payment was nearly a 4x return on the €29.3 million ($32.7 million) Rigontec...
...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH... ...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
...its third life sciences fund included acquisitions of NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH... ...front plus up to $975 million in milestones, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH... ...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH... ...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec... ...Ingelheim GmbH, Ingelheim, Germany
Mary Romeo
Boehringer Ingelheim GmbH
Flanders Institute for Biotechnology (VIB)
GlaxoSmithKline plc
Merck & Co. Inc.
Okairos AG
Rigontec GmbH
Aelin...
...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH... ...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec... ...BioCentury Extra, Dec. 11, 2017) .
Mary Romeo
Boehringer Ingelheim GmbH
Flanders Institute for Biotechnology (VIB)
Merck & Co. Inc.
Rigontec GmbH
Aelin...
...Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria... ...two therapeutics companies, two medtechs and a diagnostics company. One, the acquisition of immuno-oncology company Rigontec GmbH... ...milestones. The upfront payment was nearly a 4x return on the €29.3 million ($32.7 million) Rigontec...
...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH... ...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
...its third life sciences fund included acquisitions of NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH... ...front plus up to $975 million in milestones, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
...that could exceed 5x returns include exits from NASH company Akarna Therapeutics Ltd., immuno-oncology company Rigontec GmbH... ...Allergan plc (NYSE:AGN) acquired Akarna in 2016, while Merck & Co. Inc. (NYSE:MRK) acquired Rigontec...
...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH... ...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec... ...Ingelheim GmbH, Ingelheim, Germany
Mary Romeo
Boehringer Ingelheim GmbH
Flanders Institute for Biotechnology (VIB)
GlaxoSmithKline plc
Merck & Co. Inc.
Okairos AG
Rigontec GmbH
Aelin...
...early stage start-ups, including immuno-oncology and vaccine companies. At least two portfolio companies, immunotherapy play Rigontec GmbH... ...have achieved exits. Merck & Co. Inc. (NYSE:MRK) said in September 2017 it would acquire Rigontec... ...BioCentury Extra, Dec. 11, 2017) .
Mary Romeo
Boehringer Ingelheim GmbH
Flanders Institute for Biotechnology (VIB)
Merck & Co. Inc.
Rigontec GmbH
Aelin...